Press release
Page 1
Navantor ™ NEWS RELEASE AvantorⓇ to Acquire Masterflex® ; Expands Proprietary Single - Use Offering for Bioproduction 9/7/2021 - Masterflex® is a leading global manufacturer of peristaltic pumps and aseptic single - use fluid transfer technologies - Strengthens Avantor's offering across all bioproduction platforms including mAbs , cell and gene therapy and mRNA , and supports both therapy and vaccine manufacturing including COVID - 19 - Transaction is expected to enhance Avantor's revenue growth and margin profile and be accretive to Adjusted Earnings per share ( EPS ) in year 1 post - acquisition RADNOR , Pa . , Sept. 7 , 2021 / PRNewswire / -- Avantor , Inc. ( NYSE : AVTR ) , a leading global provider of mission - critical products and services to customers in the life sciences and advanced technologies & applied materials industries , today announced that it has entered into a definitive agreement to acquire the Masterflex bioprocessing business and related assets ( collectively " Masterflex " ) of Antylia Scientific , a privately held , portfolio company of investment firms GTCR and Golden Gate Capital . The all - cash transaction is valued at $ 2.9 billion , subject to final adjustments at closing . Given anticipated tax benefits from the transaction structure , the net purchase price is approximately $ 2.7 billion . Headquartered in Vernon Hills , Illinois , Masterflex is a leading global manufacturer of peristaltic pumps and aseptic single - use fluid transfer technologies with estimated 2022 revenues of approximately $ 300 million . The acquisition strengthens Avantor's offering across all bioproduction platforms including monoclonal antibodies ( mAbs ) , cell and gene therapy and mRNA , and supports both therapy and vaccine manufacturing including COVID - 19 . For more than 50 years , Masterflex has been providing industry - leading fluid transfer technologies central in the execution of research and production workflows . " The acquisition of Masterflex reflects our commitment to the biopharma industry , and our ability to identify and execute on value - creation opportunities , " said Michael Stubblefield , President and CEO of Avantor . " The business 1